Memo Therapeutics raises €18.0M Series C round

The CHF 20 million funding, part of an extension of its Series C financing, will be used to bolster the clinical advancement of Memo Therapeutics AG's lead asset, AntiBKV, expanding the Phase II trial with a dose evaluation extension to be the largest BK viremia therapeutic study ever conducted in kidney transplant recipients. The funding will further support the development of MTx's pipeline by leveraging its B-cell screening platform to select best-in-class humanized antibodies in other viral infections and oncology.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEHaMmOpUxtFHGpvy3hCZTHvRCACVkgJos-HnVYkzhu0ts2llzHyt6EOOysH-h06cdgJy8X_KqLgmZQ_hz7gQxMipQTKAsAspVwaM2yVS-ek0ESLoh_QbB0nKQAHpo8cd0YVRq0wRMxB8PfhLkxcw8fVExmc6goTO0be6A-PZrSRMFtxcU1LWyr3NiSv_i3vWaEBaU1_DVw5JveiElo7mSmkDIj